The clinical relevance of the DIGAMI study and related preclinical observations has led to the hypothesis that inhibition of SUR2 could potentially impair coronary vasodilation [108] and increase the risk of sudden cardiac arrest through effects on both SUR1 and SUR2 [109]. Here, ABCC9 is linked to sudden cardiac arrest.